NEW YORK, Dec. 12 – Celera Genomics and Merck said Wednesday that they had agreed to extend their osteoporosis drug discovery deal for a sixth year.

This is the fourth extension for the research collaboration. The original deal dates back to November 1996 when Celera’s South San Francisco operations, then Axys Pharmaceuticals, penned a two-year drug discovery deal with Merck.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.